title: Relationship between treatment-induced changes in left ventricular mass and blood pressure in black african hypertensive patients: results of the Baragwanath Trial.
abstract: BACKGROUND
  In a single-center study, we compared to what extent changes in conventional and ambulatory blood pressure (BP) predicted regression of left ventricular mass (LVM) index in response to antihypertensive treatment in previously untreated and treated patients with sustained hypertension.
  
  
  RESULTS
  We enrolled 173 black African patients who, off treatment, had a daytime diastolic BP ranging from 90 to 114 mm Hg. Antihypertensive drugs were titrated and combined to reduce the daytime diastolic BP below 90 mm Hg. Echocardiograms were obtained at baseline and follow-up. Mean systolic/diastolic clinic BP, 24-hour BP, and LVM index were similar in previously untreated (n=64) and previously treated (n=109) patients and averaged 171/102 mm Hg, 151/97 mm Hg, and 118 g/m2, respectively. At 4 months, these values had decreased (P<0.001) by 26/12 mm Hg, 23/14 mm Hg, and 14 g/m2 in previously untreated patients and by 22/9 mm Hg, 21/13 mm Hg, and 19 g/m2 in previously treated patients. In the previously untreated patients, the regression in LVM index correlated to a similar degree (P=0.09) with the decreases in the conventional (r=0.34; P=0.005) and the 24-hour (r=0.26; P=0.04) systolic BP. In the previously treated patients, the corresponding correlations were 0.02 (P=0.82) and -0.10 (P=0.32), respectively. Compared with the 24-hour systolic BP, automated oscillometric measurements of systolic BP obtained at the clinic yielded similar results.
  
  
  CONCLUSIONS
  In previously untreated patients with sustained hypertension followed at a single center, reductions in clinic and ambulatory systolic pressure in response to antihypertensive treatment equally predicted the regression in LVM index.
authors.affiliation: Department of Cardiology, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa. dskudi@icon.co.za
authors.forename: Daniel
authors.initials: D
authors.lastname: Skudicky
authors.forename: Pinhas
authors.initials: P
authors.lastname: Sareli
authors.forename: Elena
authors.initials: E
authors.lastname: Libhaber
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Candy
authors.forename: Ivo
authors.initials: I
authors.lastname: Radevski
authors.forename: Zdravska
authors.initials: Z
authors.lastname: Valtchanova
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Tshele
authors.forename: Lutgarde
authors.initials: L
authors.lastname: Thijs
authors.forename: Ji-Guang
authors.initials: JG
authors.lastname: Wang
authors.forename: Jan A
authors.initials: JA
authors.lastname: Staessen
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D044383:Black People; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003971:Diastole; D004232:Diuretics / Q000627:therapeutic use; D004452:Echocardiography; D004656:Enalapril / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D017379:Hypertrophy, Left Ventricular / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use; D010349:Patient Compliance; D012044:Regression Analysis; D013019:South Africa; D013599:Systole; D014700:Verapamil / Q000627:therapeutic use
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D004232:Diuretics; D006852:Hydrochlorothiazide; D008750:Methyldopa; D004656:Enalapril; D014700:Verapamil; D009543:Nifedipine